Royalty Pharma announces $7.5 million gift to Blood Cancer United to expand Therapy Acceleration Program
Royalty Pharma acquires royalty interest in AstraZeneca's cliramitug for up to $425 million from Neurimmune
Brixton Metals Announces Upsize of Previously Announced Non-Brokered Private Placement to $8 Million and Closing of Second Tranche
BriaCell and BriaPro Present Positive Preclinical Immunotherapy Data Across Four Posters at SITC 2026
